NBI 640756

Drug Profile

NBI 640756

Alternative Names: NBI-640756

Latest Information Update: 01 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurocrine Biosciences
  • Class Small molecules
  • Mechanism of Action Nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Essential tremor

Most Recent Events

  • 14 Feb 2017 Neurocrine plans a phase II trial for Essential tremor
  • 03 Aug 2016 Neurocrine Bioscience completes a phase I trial in Essential tremor in USA
  • 03 Aug 2016 Neurocrine Biosciences initiates enrolment in a phase I trial for Essential tremor
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top